Advances in immune checkpoint inhibitors induced-cardiotoxicity

Immune checkpoint inhibitors (ICIs) are approved as the first-line drug for treating many cancers and has shown significant survival benefits; however, it also causes immune-related adverse events (irAEs) while activating the immune system, involving multiple organs. Among them, cardiovascular immun...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiang Li, Wenying Peng, Jiao Wu, Sai-Ching Jim Yeung, Runxiang Yang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-02-01
Edice:	Frontiers in Immunology
Témata:	cardiotoxicity immune checkpoint inhibitors immune-related adverse events Myocarditis Pericarditis Vasculitis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1130438/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!